Management
`
`Corporate Information
`
`Financial Information
`
`Careers
`
`Specialty Pharmaceuticals
`
`Home
`
`About Us
`
`Our Products
`
`Partner With Us
`
`Contact Us
`
`Our experienced management team continues the company’s tradition of bringing new,
`high-quality generics to market that began more than 30 years ago.
`
`Joseph Barbarite
`Senior Vice President, Corporate Quality and Compliance
`Mr. Barbarite is Senior Vice President and is responsible for Quality Assurance and Compliance. With
`more than 25 years of experience, he has successfully managed FDA Inspections and numerous site PAI
`projects that have all resulted in first pass site approval by FDA. He has also established a Drug Safety
`Group, outsourced call center and pharmacovigilance evaluation, and implemented a program for major
`remediation preventing regulatory action. Prior to Par Pharmaceutical, he spent eight years at Forest
`Laboratories in Quality Management Positions such as Senior Director, PR&D QA and Director, Quality
`Assurance. Mr. Barbarite received a BS in Biology from Fordham University.
`
`Renee Kenney
`Senior Vice President, Sales (Generic)
`Ms. Kenney is Senior Vice President, Generic Sales and is responsible for achieving sales goals and
`initiatives while maximizing customer relationships. During her 10 years with Par, she held various
`positions in Sales and was promoted to her current position in April 2007. Prior to Par Pharmaceutical, she
`served as National Account Manager, Central Region and Director of Sales Administration at Barr
`Laboratories; and Material Manager and Manager, Marketing Administration at Duramed Pharmaceuticals.
`Ms. Kenney was also Manager, Contract Sales at Ascot Pharmaceuticals and Bid Coordinator, Assistant
`Contract Manager at Roxanne Laboratories. She earned her Associate Degree in Business Administration
`from Franklin University.
`
`Robert Polke
`Senior Vice President, Manufacturing and Technical Operations
`Mr. Polke is Senior Vice President, Manufacturing and Technical Operations and is responsible for
`commercial production, validation and technical support of Par Pharmaceutical products. Before joining
`the company, he was Vice President, Operations at Indigo Pharmaceuticals and Chief Operating Officer at
`BML Pharmaceuticals. Prior to BML Pharmaceuticals, Mr. Polke was Director of Operations at Circa
`Pharmaceuticals and Supervisor of Solid Dosage Manufacturing Operations at Pfizer Inc., Central
`Research Division. He earned both a BS degree in Chemistry and an MBA in Executive Management from
`St. John’s University.
`
`Michelle Bonomi-Huvala
`Senior Vice President, Corporate Regulatory Affairs
`Ms. Bonomi-Huvala is Vice President of Regulatory Affairs and is responsible for the development and
`implementation of regulatory strategies for various stages of drug development, drug submission, product
`launch and post-approval activities. In addition to a successful track record of numerous generic drug
`submissions and approvals, Ms. Bonomi-Huvala played a key leadership role in gaining FDA market
`approval of the company’s first NDA. Prior to joining Par, she worked in various capacities in Quality
`Assurance and Regulatory Affairs at Barr Laboratories, now Teva Pharmaceuticals. She earned a BS in
`Nutrition & Health from Marymount College.
`
`Chad Gassert
`Vice President, Business Development and Licensing
`Mr. Gassert is a Vice President at Par Pharmaceutical, where he leads the company’s generic business
`development efforts. Mr. Gassert joined Par in 2005 and has more than 11 years' experience in the
`pharmaceutical industry, serving positions in product development, manufacturing operations, project
`management and business development. Mr. Gassert graduated with a BSc from the University of
`Delaware and an MSc in Engineering Management from the New Jersey Institute of Technology.
`
`Suketu Sanghvi, PhD
`Vice President, Formulation Development
`Dr. Sanghvi is Vice President, Formulation Development, provides CMC leadership in drug development,
`and manages the Formulation Department for Development of Controlled Release Dosage Form. He also
`served as Associate Director, Formulation. Prior to his current position, Dr. Sanghvi was a Senior Director,
`Product Development at Novel Laboratories. Other positions included Senior Manager, Formulation at
`Progenics Pharmaceuticals and Principal Scientist, Formulation at Purdue Pharma LP. He began his
`career at Forest Laboratories, where he served as Manager, Formulation and Manager, Process
`
`
`
`http://www.parpharm.com/generics/index.php?option=com_content&view=article&id=50&Itemid=72
`
`1/2
`
`JAZZ EXHIBIT 2023
`Amneal Pharms. et al. (Petitioners) v. Jazz Pharms., Inc. (Patent Owner)
`Case IPR2015-00554
`
`Page 1 of 2
`
`

`
`Management
`Validation. Dr. Sanghvi received his B.Pharm. from the University of Mysore, India; MSc from the Faculty of
`Pharmacy, University of Saskatchewan; and PhD from the Faculty of Pharmacy, University of Toronto.
`
`Michael Altamuro
`Vice President, Marketing & Business Analytics
`Mr. Altamuro serves as Vice President, Marketing & Business Analytics and oversees marketing and
`forecasting efforts as well as the Generic Contracts and Pricing Group. He joined the company in 2007 as
`Director, Pipeline Product Management. Previously, Mr. Altamuro was Director, Sales Forecasting &
`Market Analysis and Associate Director, Financial Forecasting & Strategy, at Barr Pharmaceuticals. He
`also held various accounting/managerial positions in the financial services industry. Mr. Altamuro received
`his BBA degree in Accounting at Siena College and earned an MBA in Corporate Finance from Fairleigh
`Dickinson University.
`
`Additional Management Profiles
`To learn more about the management of our other divisions, please visit:
`
`
`
`© 2010 Par Pharmaceutical Companies, Inc. Par Pharmaceutical is a division of Par Pharmaceutical Companies, Inc.
`
`Sitemap | Terms of Use | Privacy Policy | Compliance | Public Re
`
`http://www.parpharm.com/generics/index.php?option=com_content&view=article&id=50&Itemid=72
`
`2/2
`
`Page 2 of 2